7/27/2017
`
`lebwohl-de OR lebwohI-d NOT IebwohI-dj - PubMed - NCBI
`
`PubMed
`
`V
`
`IebwohI-de OR IebwohI-d NOT lebwohI-dj
`
`Format: Summary
`
`Sort by: Most Recent
`
`Per page: 100
`
`Search results
`
`Items: 71
`
`Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human
`1. Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
`
`Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT,
`Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter
`H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.
`J Clin Oncol. 2016 Feb 10;34(5):419-26.doi:10.1200/JCO.2014.60.1971.Epub 2015 Oct 26.
`PMID: 26503204
`Free PMC Article
`
`Everolimus
`
`lus exemestane in ostmeno ausal atients with HR + breast cancer: BOLERO-2 final
`
`2.
`
`progression-free survival analysis.
`Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B,
`Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D,
`Rugo HS.
`Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25. Erratum in: Adv Ther. 2014
`Sep;31(9):1008-9.
`PMID: 24158787
`
`Free PMC Article
`
`Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III
`3. GRANITE-1 study.
`
`Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH,
`Ferry D, Tebbutt NC, AI-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E.
`J Clin Oncol. 2013 Nov 1 ;31(31):3935-43. doi: 10.1200/JCO.2012.48.3552. Epub 2013 Sep 16.
`PMID: 24043745
`
`Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
`
`4- Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W.
`Ann N YAcad Sci. 2013 Ju|;1291:14-32.doi:10.1111/nyas.12122.Epub 2013 May 9. Review.
`PMID: 23659703
`
`Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
`
`5- Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, lwata H,
`Geberth M, Hart LL, Hadji P, EI-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard Kl.
`J Natl Cancer Inst. 2013 May 1 ;105(9):654-63. doi: 10.1093/jnci/djt026. Epub 2013 Feb 19.
`PMID: 23425564
`
`Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic
`
`| m han ioleiom omatosis EXIST-2 : a multicentre randomised double-blind
`lacebo-controlled trial.
`
`6.
`
`Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N,
`Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K.
`Lancet. 2013 Mar 9;381(9869):817-24.
`PMID: 23312829
`
`Par Pharm., Inc.
`Exhibit 1097
`
`https://www.ncbi.n|m.nih.gov/pubmed
`
`1/10
`
`Par Pharm., Inc. v. Novartis AG
`
`case IPR2015-01479
`
`Ex. 1097-0001
`
`Ex. 1097-0001
`
`

`

`7/27/201 7
`
`lebwohl-de OR lebwohl-d NOT IebwohI-dj - PubMed - NCBI
`
`Efficacy and safety of everolimus for subependymal giant cell astrocflomas associated with tuberous sclerosis
`com lex EXIST-1 : a multicentre randomised
`lacebo-controlled hase 3 trial.
`
`Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu
`JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T,
`Jozwiak S.
`
`Lancet. 2013 Jan 12:381 (9861 ):125-32. doi: 10.1016/SO140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan
`12;381(9861):116.
`PMID: 23158522
`
`Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT)
`model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma.
`
`Korhonen P, Zuber E, Branson M, Hollaender N, Yateman N, Katiskalahti T, Lebwohl D, Haas T.
`J Biopharm Stat. 2012;22(6):1258-71. doi: 10.1080/10543406.2011.592233.
`PMID: 23075021
`
`Vascular densit anal sis in colorectal cancer atients treated with vatalanib PTK787/ZK222584 in the
`randomised CONFIRM trials.
`
`Giatromanolaki A, Koukourakis Ml, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava
`T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group.
`Br J Cancer. 2012 Sep 25;107(7):1044-50.doi:10.1038/bjc.2012.369.Epub 2012 Aug 21.
`PM|D122910317
`Free PMC Article
`
`10.
`
`lntratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with
`chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
`
`Wilson PM, Yang D, Azuma M, Shi MM, Danenberg KD, Lebwohl D, Sherrod A, Ladner RD, Zhang W,
`Danenberg PV, Trarbach T, Folprecht G, Meinhardt G, Lenz HJ.
`Pharmacogenomics J. 2013 Oct;13(5):410-6.doi:10.1038/tpj.2012.23.Epub 2012 Jun 5.
`PMID: 22664478
`
`11.
`
`Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
`
`Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard Kl,
`Lebrun F, Beck JT, Ito Y, Yardley D, Deleu l, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D,
`Hortobagyi GN.
`N Engl J Med. 2012 Feb 9;366(6):520-9.doi:10.1056/NEJMoa1109653.Epub 2011 Dec 7.
`PMID:22149876
`FreeArticle
`
`Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours
`associated with carcinoid s ndrome RADIANT-2 : a randomised
`lacebo-controlled
`base 3 stud .
`
`12.
`
`Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin
`
`EM, Oberg K, Van Cutsem E, Yao JC; RADIANT—2 Study Group.
`Lancet. 2011 Dec 10;378(9808):2005-2012. doi: 10.1016/80140-6736(11)61742-X. Epub 2011 Nov 25.
`PMID: 22119496
`
`TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-
`1 and -2 clinical trials.
`
`13.
`
`Grimminger PP, Shi M, Barrett C, Lebwohl D, Danenberg KD, Brabender J, Vigen CL, Danenberg PV, Winder T,
`Lenz HJ.
`
`Pharmacogenomics J. 2012 Oct;12(5):404-11.doi:10.1038/tpj.2011.29.Epub 2011 Jul 26.
`PMID: 21788964
`
`14.
`
`Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with
`PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.
`
`https://www.ncbi.nlm .nih.gov/pubmed
`
`2/10
`
`Ex. 1097-0002
`
`Ex. 1097-0002
`
`

`

`7/27/201 7
`
`lebwohl-de OR lebwohI-d NOT Iebwohl-dj - PubMed - NCBI
`
`Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava
`T, Laurent D, Meinhardt G, Harris AL.
`Clin Cancer Res. 2011 Jul 15;17(14):4892-900.doi:10.1158/1078-0432.CCR-10-2918.Epub 2011 Jun 1.
`PMID: 21632858
`Free PMC Article
`
`15.
`
`Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK
`222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal
`adenocarcinoma.
`
`Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K,
`Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D.
`J Clin Oncol. 2011 May 20;29(15):1997-2003.doi:10.1200/JCO.2010.29.4496.Epub 2011 Apr 4.
`PMID: 21464406
`
`16.
`
`Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without
`PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
`
`Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T,
`Lebwohl D, Meinhardt G, Laurent D, Lin E.
`J Clin Oncol. 2011 May 20;29(15):2004-10. doi: 10.1200/JCO.2010.29.5436. Epub 2011 Apr 4.
`PMID:21464401
`
`17.
`
`18.
`
`Research and innovation in the development of everolimus for oncology.
`
`Lebwohl D, Thomas G, Lane HA, O'Reilly T, Escudier B, Yao JC, Pavel M, Franz D, Berg W, Baladi JF, Stewart
`J, Motzer RJ.
`Expert Opin Drug Discov. 2011 Mar;6(3):323-38. doi: 10.1517/174604412011558079. Epub 2011 Feb 17.
`PMID: 22647206
`
`Everolimus for advanced pancreatic neuroendocrine tumors.
`
`Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG,
`
`Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K; RAD001 in Advanced
`Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
`N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
`PMID: 21306238
`Free PMC Article
`
`19.
`
`A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous
`dosing schedule in patients with advanced cancer.
`
`Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D,
`Laurent D.
`
`Anticancer Res. 2010 Jun;30(6):2335-9.
`PMID: 20651389
`
`20.
`
`Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of
`cfiotoxic chemotherapy: a phase II trial.
`
`Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T,
`Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA,
`Wiedenmann B.
`
`J Clin Oncol. 2010 Jan 1;28(1):69-76.doi:10.1200/JCO.2009.24.2669.Epub 2009 Nov 23.
`PMID: 19933912
`Free PMC Article
`
`21.
`
`Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
`
`Yuan R, Kay A, Berg WJ, Lebwohl D.
`J Hematol Oncol. 2009 Oct 27;2:45. doi: 10.1186/1756-8722-2-45. Review.
`PMID: 19860903
`Free PMC Article
`
`https://www.ncbi.n|m .nih.gov/pubmed
`
`3/10
`
`Ex. 1097-0003
`
`Ex. 1097-0003
`
`

`

`7/27/201 7
`
`lebwohl-de OR lebwohl-d NOT Iebwohl-dj - PubMed - NCBI
`
`22.
`
`Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.
`
`Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J.
`Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PP0.0b01393181b905ec. Review.
`PMID: 19826358
`
`Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase
`
`III trial.
`
`23.
`
`Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Griinwald V, Thompson JA, Figlin RA,
`Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group.
`Lancet. 2008 Aug 9;372(9637):449—56. doi: 10.1016/SO140-6736(08)61039-9. Epub 2008 Jul 22.
`PMID: 18653228
`
`24.
`
`Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid
`tumors who have failed standard therapy.
`Awada A, Piccart MJ, Jones SF, Peck RA, Gil T, Lebwohl D, Wu CY, Burris HA 3rd.
`Cancer Chemother Pharmacol. 2009 Feb;63(3):417-25.doi:10.1007/300280-008-0751-5.Epub 2008 Apr 29.
`PMID: 18446338
`
`25.
`
`Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a
`phase I tumor pharmacodynamic study in patients with advanced solid tumors.
`
`Tabernero J, Rojo F, Calvo E, Burris H, Judson l, Hazell K, Martinelli E, Ramon y Cajal S, Jones 8, Vidal L,
`Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J.
`J Clin Oncol. 2008 Apr 1 ;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Epub 2008 Mar 10. Erratum in: J Clin Oncol. 2010 Dec
`20;28(36):5350.
`PMID: 18332469
`
`26.
`
`Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
`
`Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM.
`J Clin Oncol. 2008 Jan 10;26(2):332-3; discussion 333-4. doi: 10.1200/JCO.2007.14.7249. No abstract available. Erratum in: J Clin
`Oncol.2008 Apr 20;26(12):2066.
`PMID: 18182676
`
`Phase II clinical trial of ixabe ilone BMS-247550 an e othilone B analo
`metastatic breast cancer.
`
`27.
`
`in atients with taxane-resistant
`
`Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P,
`
`Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M.
`J Clin Oncol. 2007 Aug 10;25(23):3399-406. Epub 2007 Jul 2.
`PMID: 17606975
`
`28.
`
`Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose
`tumors have failed first-line platinum-based chemotherapy.
`Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C,
`
`McHenry B, Lebwohl D, Peck R, Edelman MJ.
`J Clin Oncol. 2007 Aug 10;25(23):3448—55. Epub 2007 Jul 2. Erratum in: J Clin Oncol. 2007 Nov 20;25(33):5339. Edelman, Mark
`[corrected to Edelman, Martin J].
`PMID: 17606973
`
`
`in atients with
`Phase II clinical trial of ixabe ilone EMS-247550 an e othilone B analo
`as first-line thera
`
`29.
`
`metastatic breast cancer previously treated with anthracycline chemotherapy.
`
`Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl
`D, Ezzeddine R, Curé H.
`J Clin Oncol. 2007 Aug 10;25(23):3415-20. Epub 2007 Jul 2.
`
`https://www.ncbi.nlm .nih.gov/pubmed
`
`4/10
`
`Ex. 1097-0004
`
`Ex. 1097-0004
`
`

`

`7/27/201 7
`
`PMID: 17606972
`
`lebwohl-de OR lebwohl-d NOT IebwohI-dj - PubMed - NCBI
`
`Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimusl-
`
`30.
`
`letrozole clinical program.
`Lane HA, Lebwohl D.
`Semin Oncol. 2006 Apr;33(2 Suppl 7):S18-25. Review.
`PMID: 16730273
`
`A multi-center phase II study of EMS-247550 (lxabepilone) by two schedules in patients with metastatic gastric
`31. adenocarcinoma previously treated with a taxane.
`
`Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA 3rd, Lebwohl D, Mullaney B.
`Invest New Drugs. 2006 Sep;24(5):441-6.
`PMID: 16586011
`
`Biomarkers for assessment of harmacolo ic activit
`
`for a vascular endothelial
`
`rowth factor VEGF rece tor
`
`32.
`
`inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis
`model to phase I studies in patients with advanced colorectal cancer with liver metastases.
`
`Lee L, Sharma 8, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward
`WP, Drevs J, Lebwohl D, Wood J, McSheehy PM.
`Cancer Chemother Pharmacol. 2006 Jun;57(6):761-71. Epub 2005 Sep 20.
`PMID: 16172907
`
`Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver
`33-W
`
`Mross K, Drevs J, Mijller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY,
`Giinther C, Laurent D, Unger C.
`EurJ Cancer. 2005 Jun;41(9):1291-9.
`PMID: 15939265
`
`Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-
`
`34.
`
`refractory prostate cancer.
`
`Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C,
`Koriakine 0, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L; Genitourinary Tract Group of the EORTC.
`Oncology. 2005;68(1):2-9. Epub 2005 Feb 28.
`PMID: 15741753
`
`Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular
`35. endothelial
`rowth factor rece tor VEGFR t rosine kinase inhibitor in atients with advanced colorectal cancer
`
`from two phase I trials.
`
`Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL,
`Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.
`Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.
`PMID: 15705616
`
`Phase II stud of oral bis aceto ammine dichloro c clohexamine
`36. dail x 5 in hormone refractor
`rostate cancer HRPC .
`
`latinum IV JM-216 EMS-182751
`
`iven
`
`Latif T, Wood L, Connell C, Smith DC, Vaughn D, Lebwohl D, Peereboom D.
`Invest New Drugs. 2005 Jan;23(1):79-84.
`PMID: 15528984
`Free Article
`
`Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3
`tyrosine kinase inhibitor, PKC412.
`
`37.
`
`https://www.ncbi .nlm .nih.gov/pubmed
`
`5/10
`
`Ex. 1097-0005
`
`Ex. 1097-0005
`
`

`

`7/27/2017
`
`lebwohl-de OR lebwohI-d NOT IebwohI-dj - PubMed - NCBI
`
`Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P,
`Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.
`Blood. 2005 Jan 1;105(1):54-60. Epub 2004 Sep 2.
`PMID:15345597
`FreeArticle
`
`PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
`
`38- Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg
`D, Clark J, Gilliland DG, Griffin JD.
`Ann Hematol. 2004;83 Suppl 1:889-90. No abstract available.
`PMID: 15124689
`
`Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
`
`39- Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, Griffin T, Lebwohl DE, Liebes L, Muggia F,
`Horwitz SB.
`
`Clin Cancer Res. 2004 Feb 15;10(4):1289-98.
`PMID: 14977827
`Free Article
`
`henox ethanamine BMS-217380-01 combined with
`Phase III stud ofN N-dieth l-2- 4- hen Imeth |
`40. doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada
`
`Clinical Trials Group Study MA.19.
`
`Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J,
`Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K; National Cancer
`Institute of Canada Clinical Trials Group Study MA.19.
`J Clin Oncol. 2004 Jan 15;22(2):269-76.
`PMID: 14722035
`
`Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on
`41. a daily schedule for five days.
`
`Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D,
`Lebwohl D, Bates S, Kotz H, Fojo T.
`J Clin Oncol. 2003 May 1 ;21(9):1866-73.
`PMID: 12721265
`
`Phase I stud of JM-216 an oral
`
`latinum analo ue in combination with aclitaxel in atients with advanced
`
`42. malignancies.
`
`Jones S, Hainsworth J, Burris HA 3rd, Thompson D, Raefsky E, Johnson V, Calvert S, Bulanhagui C, Lebwohl
`D, Greco FA.
`Invest New Drugs. 2002 Feb;20(1):55-61.
`PMID: 12008664
`
`A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.
`
`43- Trudeau M, Stuart G, Hirte H, Drouin P, Plante M, Bessette P, Dulude H, Lebwohl D, Fisher B, Seymour L.
`Gynecol Oncol. 2002 Feb;84(2):327-31.
`PMID: 11812095
`
`Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.
`
`44- Amorino GP, Freeman ML, Carbone DP, Lebwohl DE, Choy H.
`IntJ Radiat Oncol Biol Phys. 1999 May 1 ;44(2):399-405.
`PMID: 10760436
`
`New developments in chemotherapy of advanced breast cancer.
`
`45- Lebwohl DE, Canetta R.
`
`https://www.ncbi .nlm .nih.gov/pubmed
`
`6/10
`
`Ex. 1097-0006
`
`Ex. 1097-0006
`
`

`

`7/27/201 7
`
`lebwohl-de OR lebwohI-d NOT lebwohl-dj - PubMed - NCBI
`
`Ann Oncol.1999;10 Suppl 6:139-46. Review.
`PMID: 10676565
`
`46.
`
`5-year results of dose-intensive seguential adiuvant chemotherapy for women with high-risk node-positive
`breast cancer: A phase II study.
`Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B,
`
`Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L.
`J Clin Oncol. 1999 Apr;17(4):1118.
`PMID: 10561169
`
`Phase II trial ofN N-dieth |-2-4- hen Imeth | henox ethanamine.HC| and doxorubicin chemothera
`
`In
`
`47.
`
`metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.
`
`Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E.
`J Clin Oncol.1999 Nov;17(11):3431-7.
`PMID: 10550138
`
`48.
`
`Seguential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer:
`feasibility and efficacy.
`
`Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown
`JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.
`J Clin Oncol. 1999 Jan;17(1):93-100.
`PMID: 10458222
`
`lus leucovorin and bis-acetato-ammine-dichloro-c clohex lamine-
`A hase | stud of oral uracil/florafur UFT
`latinum |V JM-216 each iven over 14 da 5 ever 28 da 3.
`
`49.
`
`DeMario MD, Ratain MJ, Vogelzang NJ, Mani S, Vokes EE, Fleming GF, Melton K, Johnson 8, Benner S,
`Lebwohl D.
`
`Cancer Chemother Pharmacol. 1999;43(5):385-8.
`PMID: 10100593
`
`50.
`
`51.
`
`52.
`
`Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.
`Lebwohl D, Canetta R.
`EurJ Cancer. 1998 Sep;34(10):1522—34. Review.
`PMID: 9893623
`
`Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.
`
`Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G,
`Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L.
`Cancer Invest. 1998;16(2):67-71. No abstract available.
`PMID: 9512671
`
`Sequential adiuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
`
`Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M,
`Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L.
`Semin Oncol. 1996 Feb;23(1 Suppl 1):58-64.
`PMID: 8629040
`
`53.
`
`Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
`Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE,
`
`Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L.
`J Clin Oncol. 1996 Jan;14(1):58-65.
`PMID: 8558221
`
`https://www.ncbi.n|m .nih.gov/pubmed
`
`7/10
`
`Ex. 1097-0007
`
`Ex. 1097-0007
`
`

`

`7/27/201 7
`
`lebwohl-de OR lebwohI-d NOT IebwohI-dj - PubMed - NCBI
`
`54.
`
`Seguential adiuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving
`four or more axillary nodes.
`
`Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N,
`Fennelly D, et al.
`Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.
`PMID: 8643965
`
`55.
`
`56.
`
`57.
`
`Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
`Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH Jr.
`J Cell Physiol. 1995 Oct;165(1):212-21.
`PMID: 7559803
`
`Herbimycin A induces the 20 S proteasome- and ubiguitin-dependent degradation of receptor tyrosine kinases.
`
`Sepp-Lorenzino L, Ma 2, Lebwohl DE, Vinitsky A, Rosen N.
`J Biol Chem. 1995 Jul 14;270(28):16580-7.
`PMID: 7622464
`Free Article
`
`Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
`
`Sepp-Lorenzino L, Rosen N, Lebwohl DE.
`Cell Growth Differ. 1994 Oct;5(10):1077-83.
`PMID: 7848909
`Free Article
`
`aclitaxel
`Taxol
`breast cancer.
`
`58.
`
`lus recombinant human ranuloc ecolon -stimu|atin factor in the treatmentof metastatic
`
`Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Hudis CA,
`Surbone A, et al.
`Oncology. 1994 Oct;51 Suppl 1:33-9.
`PMID: 7526308
`
`59.
`
`A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.
`
`Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, Serve S, Timaul M, Bol R, Borgen P, Rosen N.
`Oncogene. 1994 Jul;9(7):1925-9.
`PMID: 8208539
`
`60.
`
`Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer
`1%
`
`Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen Pl.
`Cancer. 1994 Jul 1;74(1):74-7.
`PMID: 8004585
`Free Article
`
`61.
`
`Taxol and recombinant human granulocfle colony-stimulating factor, an active regimen as initial therapy for
`metastatic breast cancer. A preliminary report.
`Reichman BS, Seidman AD, Crown JP, Heelan R, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A,
`Currie V, et al.
`Ann N Y Acad Sci. 1993 Nov 30:698z398-402. No abstract available.
`PMID: 7506506
`
`Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic
`breast cancer.
`
`62.
`
`Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V,
`Hudis CA, et al.
`J Clin Oncol. 1993 Oct;11(10):1943-51.
`
`https://www.ncbi.n|m .nih.gov/pubmed
`
`8/10
`
`Ex. 1097-0008
`
`Ex. 1097-0008
`
`

`

`7/27/201 7
`
`PMID: 7691998
`
`lebwohl-de OR lebwohl-d NOT IebwohI-dj - PubMed - NCBI
`
`Preliminar ex erience with aclitaxel Taxol
`the treatment of breast cancer.
`
`63.
`
`lus recombinant human ranuloc te colon -stimu|atin factor in
`
`Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA,
`Surbone A, et al.
`Semin Oncol. 1993 Aug;20(4 Suppl 3):40-5.
`PMID: 7688145
`
`64.
`
`65.
`
`66.
`
`67.
`
`68.
`
`69.
`
`Phase II trial of carboplatin and etoposide in metastatic breast cancer.
`Crown J, Hakes T, Reichman B, Lebwohl D, Gilewski T, Surbone A, Currie V, Yao TJ, Hudis C, Seidman A, et al.
`Cancer. 1993 Feb 15;71(4):1254-7.
`PMID: 8435802
`Free Article
`
`Taxol plus recombinant human granulocfle-colony stimulating factor as initial and as salvage chemotherapy for
`metastatic breast cancer: a preliminary report.
`Seidman AD, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A,
`Currie V, et al.
`J Natl Cancer Inst Monogr. 1993;(15):171-5.
`PMID: 7517153
`
`Expression of inducible membrane-anchored insulin receptor kinase enhances deoxyglucose uptake.
`Lebwohl DE, Nunez l, Chan M, Rosen OM.
`J Biol Chem. 1991 Jan 5;266(1):386-90.
`PMID: 1845969
`Free Article
`
`Polylysine activates and alters the divalent cation reguirements of the insulin receptor protein tyrosine kinase.
`Rosen OM, Lebwohl DE.
`FEBS Lett. 1988 Apr 25;231(2):397-401.
`PMID: 3360145
`Free Article
`
`Synthesis, purification, and characterization of the cfioplasmic domain of the human insulin receptor using a
`baculovirus expression system.
`Herrera R, Lebwohl D, Garcia de Herreros A, Kallen RG, Rosen OM.
`J Biol Chem. 1988 Apr 25;263(12):5560-8.
`PMID: 2451671
`Free Article
`
`Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate
`postreceptor effects of insulin.
`Chou CK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A, Rosen OM.
`J Biol Chem. 1987 Feb 5;262(4):1842-7.
`PMID: 3100537
`Free Article
`
`70.
`
`The T lymphocyte response to cflochrome C. III. Relationship of the fine specificity of antigen recognition to
`maior histocompatibility complex genotype.
`
`Matis LA, Hedrick SM, Hannum C, Ultee ME, Lebwohl D, Margoliash E, Solinger AM, Lerner EA, Schwartz RH.
`J Immunol. 1982 Jun;128(6):2439-46. No abstract available.
`PMID: 6176634
`
`71.
`
`The T lymphocfie response to cfiochrome c--||. Molecular characterization of a pigeon cflochrome c
`determinant recognized by proliferating T lymphocfles of the B10.A mouse.
`
`Ultee ME, Margoliash E, Lipkowski A, Flouret G, Solinger AM, Lebwohl D, Matis LA, Chen C, Schwartz RH.
`
`https://www.ncbi.nlm .nih.gov/pubmed
`
`9/10
`
`Ex. 1097-0009
`
`Ex. 1097-0009
`
`

`

`7/27/2017
`
`lebwohl-de OR lebwohI-d NOT IebwohI-dj - PubMed - NCBI
`
`Mol Immunol. 1980 Jul;17(7):809-22. No abstract available.
`PMID: 6163966
`
`Back to top
`
`https://www.ncbi .nlm .nih.gov/pubmed
`
`10/10
`
`Ex. 1097-0010
`
`Ex. 1097-0010
`
`